WO2019213396A1 - Formulations et méthodes d'administration pour la réduction et l'élimination d'inflammations induites par des agents pathogènes dans le corps humain - Google Patents

Formulations et méthodes d'administration pour la réduction et l'élimination d'inflammations induites par des agents pathogènes dans le corps humain Download PDF

Info

Publication number
WO2019213396A1
WO2019213396A1 PCT/US2019/030401 US2019030401W WO2019213396A1 WO 2019213396 A1 WO2019213396 A1 WO 2019213396A1 US 2019030401 W US2019030401 W US 2019030401W WO 2019213396 A1 WO2019213396 A1 WO 2019213396A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
carrier composition
high purity
percent
delivery
Prior art date
Application number
PCT/US2019/030401
Other languages
English (en)
Inventor
Jaim Nulman
Original Assignee
Jaim Nulman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaim Nulman filed Critical Jaim Nulman
Publication of WO2019213396A1 publication Critical patent/WO2019213396A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present disclosure relates to the treatment of pathogen induced inflammations in the human body.
  • the present discloses provides formulations and methods for delivery of Alpha Hydroxy Acids as an active therapeutic media to inhibit nucleation sites and thus inhibit reproduction of the pathogens, hence eliminating the inflammation thereof of tissues in the human body and any mammal species.
  • microbiofilms a sticky conglomeration of pathogens
  • pathogens nucleate and are sequestered in these microbiofilms as they provide a mechanically stabile platform for the pathogens to nucleate upon, resulting in inflammation of the tissue underlying the biofilm.
  • Formation of a biofilm takes place in several stages, starting with rapid surface attachment to a body element, such as tissue, bone or teeth, followed by multilayered bacterial cell proliferation, and intercellular adhesion in an extracellular polysaccharide matrix. The presence of these microbiofilms presents three major problems.
  • pathogen communities on these surfaces represent a reservoir of pathogens that can be shed into the body, leading to a chronic infection.
  • these microbiofilms are shielded from attack by the human immune system and are often much harder to kill with medicines than their free-floating counterparts; therefore, once these pathogen communities form, they are extremely difficult to eliminate with conventional antimicrobial therapies.
  • host responses and antimicrobial therapies are often unable to eliminate pathogen growth in a biofilm, a chronic inflammatory response at the site of the biofilm results.
  • Identification of these microbiofilms requires advanced analytical techniques such as electron and laser microscopy, hence tissue or organ removal for analysis.
  • lymphoid tissue such as adenoids and tonsils, are commonly removed via surgery, and they have provided clear evidence of the presence of these microbiofilms.
  • pathogens External introduction of pathogens to the body. - This takes place via one of the following channels: airborne pathogens introduced via the nose and mouth; air, water or contact borne pathogens that come into contact with an open wound on skin, mouth, nasal, vaginal or anal tissue; pathogens that come in contact with food and hands, then introduced by ingestion through the mouth; via the urinary system; and via implant of medical devices such as orthopedic implants, teeth implants, injection such as intramuscular injection, and catheters.
  • pathogens are part of the local microbiome, which is an internal complex balanced ecosystem of bacteria within the human body. The vast majority of the microbiome is located in the digestive system. It is understood that disrupting the microbial ecosystems can cause diseases and weight gain. In addition, some diseases disrupt the human body microbial system, and this disruption is typically triggered by the type of foods eaten. The internal migration of pathogens is exacerbated by the inflammation on all or part of the internal systems due to the presence of pathogens in areas where they should not be, resulting in a biological imbalance in the different sections of these system.
  • a microbiofilm is formed serving as nucleation site for additional pathogens resulting in inflammation of the tissues covering/forming several systems in the human body.
  • the inflammation of these systems results in the inability of the body system to properly function, as well as discomfort and pain in the individual having the inflammation and infection.
  • the inflammation and infection can result in severe diseases such as cancer.
  • a medical device implant in the body such as orthopedic and teeth implants or catheters
  • Infection is a major problem in orthopedics and with teeth implants, leading to implant failure. It is a challenging task to treat these implant related infections that may lead to implant replacement and, in severe cases, may result in amputation and mortality.
  • Sources of infectious pathogens include the environment of the operating room, surgical equipment, clothing worn by medical and paramedical staff, and resident pathogens on the patient's skin and body.
  • Implant-associated infections are the result of pathogen adhesion to an implant surface and subsequent microbiofilm formation on the tissue surrounding and in contact with the implanted device.
  • Staphylococcus comprises up to two-thirds of all pathogens in orthopedic implant infections and they are the principal causative agents of two major types of infection affecting bone: septic arthritis and osteomyelitis, which involve the inflammatory destruction of joint and bone.
  • Other areas of the human body that are susceptible to pathogen induced microbiofilms include the upper respiratory, digestive, and urinary systems.
  • the digestive system includes, as a partial list, the esophagus, the mouth of the stomach, lymphoid tissues, teeth gums, etc.; the urinary system includes the uterine cervix, urinary bladder, biliary track, etc.; while the upper respiratory system includes also lymphoid tissue organs such as adenoids.
  • inflammation thereof can evolve into malignant tumors that become carcinomas.
  • Such an example is esophageal adenocarcinoma, the malignant transformation at the end of a spectrum of diseases related to gastroesophageal reflux disease, which has become the most rapidly increasing cancer in the Western world.
  • pathogens either external or internal, enter a section of the digestive or upper respiratory systems, or when certain conditions trigger an imbalance of the microbiome, the pathogens migrate, nucleate and reproduce in these areas resulting in inflammation of the tissue where they take up unwelcomed residency. All of the pathogen induced inflammations result in an increased pathogen population as a consequence of the increased surface area for pathogen nucleation and reproduction.
  • lymphoid tissues located in the esophagus, as well as adenoids and tonsils in the upper respiratory system. While these lymphoid tissues commonly provide the first line of defense against the external pathogens, they also can become infected and hence inflamed if nucleation conditions exist, hence inhibiting their functionality as well as creating other health problems, such as sleep apnea.
  • bacteria forms in the mouth as a consequence of food residue and ineffective tooth brushing, rinsing or cleaning, hence allowing a bacterial residence in the gums and resulting in accompanying inflammation, yielding what is known as periodontal or gum diseases. A direct consequence of these diseases is damage to the soft gum tissue and bone support for the teeth.
  • an effective and safe treatment that eliminates and further inhibits microbiofilms formation, and hence the ability of pathogens to nucleate, thus reducing and even eliminating the inflammation of tissues in the human body, particularly tissues of the digestive, urinary, and upper respiratory systems; and tissues surrounding medical device implants such as orthopedic and teeth implants; and long-term catheter uses, etc.
  • This treatment is accomplished by the use of a formulation based on a-tissue/system-specific carrier for Alpha-Hydroxy Acids (AHAs).
  • AHAs Alpha-Hydroxy Acids
  • the delivery method comprises a procedure that does not result in pain or inflammation of the treated tissue and thus does not interfere with the normal intake of food and liquids, and in general with any other human activity.
  • a formulation consisting of at least one Alpha Hydroxy Acid in a carrier composition useful for the treatment of inflammation arising from the presence of microbiofilms on tissues of the human body where pathogens nucleate and reproduce.
  • the formulation results in a breakdown, and at least partial elimination of, the microbiofilm.
  • AHAs being a successful developmental method of curbing harsh ageing effects in the skin and cosmeceutical industry.
  • they find their use as food additives, preservatives, and flavoring agents.
  • the use of some AHAs in the medical industry can be traced back to late 1800’s as means to ferment certain bacteria beneficial to the human body, including certain types of Streptococcus bacteria such as the thermophilius CR12 14 ; and in the food industry to preserve food longer, especially meats and poultry 15 .
  • AHAs work on the epidermis of the skin by reducing calcium ion concentration and removing calcium ions from the cell adhesions by chelation; this causes disruption in cell adhesions, and results in desquamation.
  • Table 1 lists the AHAs which are used in the pharmaceutical/cosmetic and food industries.
  • AHAs are delivered via a carrier that wets the surface of the tissue to be treated, which then interact with the surface and subsurface of the treated tissue to remove and/or inhibit the formation of microbiofilms which serve as nucleation sites for pathogens that result in tissue inflammation.
  • the removal of the microbiofilm is accomplished via disruption of the molecular bonds between the tissue and the microbiofilm in the surface and subsurface tissue resulting in dissipation of the non-bonded molecules of the microbiofilm, i.e., the removal, shrinkage and ultimate disappearance of the microbiofilm.
  • the microbiofilm 10 in one or more layers totaling on the order of 1 to 200 microns thick is present on tissue 20, such as digestive tract, upper respiratory tract, or urinary tract tissue.
  • a carrier 40 having the AHA 30 distributed therein, is coated over the microbiofilm 10, and pathogens 50 therewith, present on the surface of tissue 20.
  • the carrier 30 is coated on the microfilm 10 on the tissue 20, the AHA migrates to the pathogen 50 -microbiofilm 10 modified surface of the tissue 20 as shown in Figure 2.
  • the AHA formulation interacts with the natural surface of the tissue 20 to disassociate the microbiofilm(s), thereby allowing the body’s natural fluids and lymphocytes to remove the broken-down portions of microbiofilm and pathogens from the tissue as shown in Figure 3. Additionally, the AHA interacts with the surface of the tissue 20 in such a way that microbiofilms do not again form thereon, and hence pathogens cannot nucleate therein, reducing and even eliminating the recurrence of infection and inflammation. This is accomplished by the AHA penetrating a few nanometers inwardly of the surface of the tissue 20 thereof and thereby forming a chemically modified protective layer 60 on or at the tissue surface with surface properties that pathogens cannot again successfully nucleate on. If the formulation is taken orally, the AHA can in addition reach the tissues through the blood stream.
  • 2-Hydroxypropanoic acid, 2-Hydroxypropane- 1 ,2,3-tricarboxylic acid, and 2-Hydroxyethanoic acid, imbedded in a non-active carrier are used for the purpose of the present disclosure.
  • Typical AHA formulation consists of both the 2-Hydroxypropanoic acid and the 2-Hydroxypropane-1 ,2,3- tricarboxylic acid together, where the primary function of the formulation is affecting and eliminating the microbiofilms and affecting subsequent surface modification to eliminate future pathogen nucleation, however a formulation composed of a single AHA may also be employed.
  • the 2-Hydroxypropane-1 ,2,3-tricarboxylic acid also provides molecular binding not only to the carrier but also to the treated surface due to its carboxylic properties that enables an effective chelation function, thus enhancing the effect of the 2-Hydroxypropanoic acid as it is the more capable of the two acids in effecting the removal of the microbiofilms and the subsequent surface adjustment to eliminate further pathogen nucleation.
  • the chelation action can be further enhanced by adding calcium to the formulation up to 10% of the 2- Hydroxypropane-1 ,2,3-tricarboxylic acid concentration.
  • the 2-Hydroxyethanoic acid is used in addition to the other two acids in order to aid the treatment in extreme infection cases.
  • Table 2 list the overall and preferable concentration ranges for these three acids.
  • AHA can be delivered to the human body via ingestion of the formulation incorporated in a carrier.
  • localized or tissue specific deliveries by topical coating the infection site with the AHA are more effective.
  • the carrier is a biodegradable polymer 80 that incorporates the AHA formulation 90 therein or therewith.
  • This polymer is coated onto the medical device implant before implantation into the body, and forms an integral part of the implant.
  • the biodegradable polymer Upon contact with the surrounding tissue 20 of the body in which the implant is implanted, the biodegradable polymer releases the AHA molecule(s) therein which in turn interacts with the surface of the tissue 20 by penetrating inwardly of the tissue 20 surface thereof.
  • this interaction forms a protective layer 60 at or on the surface of the tissue 20 in such a way that microbiofilms do not form thereon, and hence pathogens cannot nucleate, reducing and even eliminating the occurrence of infection and inflammation.
  • antibiotics 100 can also be included in the biodegradable polymer in order to eliminate the pathogens that are introduced into the surface of the implanted medical device or the exposed tissue during the implant procedure, such as already used by the industry.
  • the delivery is accomplished by either direct application of a water based solution of the AHA or by ingestion of the AHA in a carrier.
  • a formulation composed of high purity sterile water or high purity sterile water with up to 10% glucose solution, and preferably in the 3 to 6% range as the carrier for the AHA(s), is used.
  • the formulation can also be delivered impregnated in a physical application carrier such as a hygienic paper towel, sponge or tampon which is sealed in an air tight envelope until its use is needed; then this application carrier is applied by hand to the vagina, two to three times a day for a period of 3 to 6 weeks, preferably four weeks.
  • a catheter can be used to introduce 1 to 100ml, preferable 5 to 20ml of the formulation two to three times a day for a period of 2 to 6 weeks preferable 3 weeks.
  • a manual compression pump is used at the external end of the catheter to push the formulation in.
  • An alternative method is the use of a three (3) way catheter where the solution is introduced by the use of a soft mechanical pump or a manual compression pump, the solution circulates into the affected area and is then cycled out via the out channel of the catheter.
  • the AHA formulation is delivered via spraying of the formulation into the nostrils.
  • the formulation uses high purity sterile water or high purity sterile water with up to 10% glucose, preferable in the 3 to 6% range as the carrier.
  • the spray is applied two to three times a day for a period of 3 to 6 weeks, preferably four weeks. Ingestion of the AHA in a carrier is also possible and the AHA arrives via the blood stream.
  • the AHA formulation is delivered integrated with tooth paste or mouth wash. These two carriers can be for regular daily use as a prophylactic against infection, in which case the formulation uses the low end of the preferred concentrations in table 2 providing an ongoing protection against bacteria accumulation. In severe cases a medicinal tooth paste or mouth wash is provided in the sense of using the high-end concentrations listed in Table 2. The medicinal toothpaste or mouth wash is applied two times a day for a period of 6 weeks.
  • the formulation is typically composed of a high viscosity, high purity, inert syrup, no vitamins, and no medical active ingredients, as the carrier for the AHAs.
  • the high viscosity syrup enables the formulation to reside for a maximum time in the inflamed areas of the upper esophagus and the tonsils; it is applied by drinking a tablespoon of the syrup twice daily over a period between 3 to 6 weeks, and preferably for four weeks.
  • the syrup is typically high purity water containing high glucose concentration to yield a Brix between 70 and 90 and typically 85, with a density greater than 1.20g/ml, and typically 1.32 g/ml.
  • the syrup used in the formulation may also be flavored in order to enhance the drinkability thereof by a human.
  • Results of testing with these formulations have shown reduction of the upper esophagus lymphatic tissue organs inflammations and eventual elimination of these inflammations as sown by non-recurrence over a period of more than five years, Table 3. These data show the efficacy of the AHA formulation on eliminating the microbiofilms so that pathogens do not have a place to nucleate and the inflammation is reduced.
  • the data was collected by visual observation of the inflammation of the lymphatic tissue organs accessible through the mouth of the patient using a relative established scale. In average, the size of the organ was 3.43 prior to the treatment and reduced to an average of 1 .21 after the treatment, an average organ size reduction by a factor of 2.83.
  • the non-re-occurrence data is an indication of the surface modification that inhibits the microbiofilm formation and subsequent pathogen nucleation.
  • the formulation consisted of 10% 2-Hydroxypropanoic acid, with 2% 2-Hydroxypropane- 1 ,2,3-tricarboxylic acid in a berry flavored syrup with a brix of 85 and a density of 1 32g/ml, taken a table spoon two times a day for a month.
  • Table 3 Upper esophagus lymphatic tissue organ size prior and after treatment, and number of re-occurrences of inflammation over a period of 5 years.
  • the formulation consists typically of a medium viscosity high purity inert syrup, no vitamins and no medical active ingredients, as the carrier for the AHAs.
  • the medium viscosity syrup enables the formulation to reside a maximum time along the inflamed areas of the middle to lower sections of the esophagus as well as the valve of the stomach. It may be applied, for example, by drinking a tablespoon of the syrup twice daily over a period between 3 to 6 weeks, and preferably for four weeks.
  • the syrup is made of high purity water containing medium glucose concentration to yield a Brix between 40 and 70 and typically 55, with a density in the 0.8g/ml to 1.20g/ml, and preferable 0.9 to 1.0.
  • the syrup used in the formulation may also be flavored in order to enhance the drinkability thereof by a human.
  • inflammation of other portions of the upper respiratory, urinary, and the digestive systems, other parts of the human body, as well as other medical implants can be also treated with the AHA formulations described here, and also alternative methods for delivery of the AHA formulations can be used including alternative methods to glucose for adjusting the viscosity of the delivery carrier such as ones made out of starch, mapply syrup, etc.
  • alternative methods for delivery of the AHA formulations including alternative methods to glucose for adjusting the viscosity of the delivery carrier such as ones made out of starch, mapply syrup, etc.
  • Soft gels with outer excipient coatings that release the formulation based on internal body temperature and/or location of the body as affected by presence of other acids/chemicals such as the difference in ambient chemistry between the stomach and the small and large intestines. This can be augmented by time release compounds commonly used in the pharmaceutical industry.
  • the outer excipient coating can also be applied at the AHA molecular level, where temperature/time release methods are used to expose the AHA to the treated surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une formulation constituée d'au moins un acide alpha-hydroxylé dans une composition d'excipient utile pour le traitement d'une inflammation résultant de la présence de microbiofilms sur des tissus du corps humain dans lesquels des agents pathogènes germent et se reproduisent. Selon un aspect, la formulation conduit à une décomposition, et au moins à une élimination partielle, du microbiofilm.
PCT/US2019/030401 2018-05-03 2019-05-02 Formulations et méthodes d'administration pour la réduction et l'élimination d'inflammations induites par des agents pathogènes dans le corps humain WO2019213396A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666467P 2018-05-03 2018-05-03
US62/666,467 2018-05-03

Publications (1)

Publication Number Publication Date
WO2019213396A1 true WO2019213396A1 (fr) 2019-11-07

Family

ID=66530543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/030401 WO2019213396A1 (fr) 2018-05-03 2019-05-02 Formulations et méthodes d'administration pour la réduction et l'élimination d'inflammations induites par des agents pathogènes dans le corps humain

Country Status (1)

Country Link
WO (1) WO2019213396A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022838A1 (fr) * 1999-09-24 2001-04-05 Societe Des Produits Nestle S.A. Eau, jus, boissons et autres aliments liquides enrichis de calcium/calcium-magnesium
US20070264353A1 (en) * 2006-05-10 2007-11-15 Medtronic, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20120070476A1 (en) * 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
JP2012211104A (ja) * 2011-03-31 2012-11-01 Ezaki Glico Co Ltd 口臭抑制用組成物
CN104352358A (zh) * 2014-12-11 2015-02-18 天津市中科健新材料技术有限公司 一种洁阴湿巾液及其制备方法
WO2015099754A1 (fr) * 2013-12-27 2015-07-02 Colgate-Palmolive Company Compositions prébiotiques de soin buccal contenant des acides carboxyliques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022838A1 (fr) * 1999-09-24 2001-04-05 Societe Des Produits Nestle S.A. Eau, jus, boissons et autres aliments liquides enrichis de calcium/calcium-magnesium
US20070264353A1 (en) * 2006-05-10 2007-11-15 Medtronic, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20120070476A1 (en) * 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
JP2012211104A (ja) * 2011-03-31 2012-11-01 Ezaki Glico Co Ltd 口臭抑制用組成物
WO2015099754A1 (fr) * 2013-12-27 2015-07-02 Colgate-Palmolive Company Compositions prébiotiques de soin buccal contenant des acides carboxyliques
CN104352358A (zh) * 2014-12-11 2015-02-18 天津市中科健新材料技术有限公司 一种洁阴湿巾液及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FERNANDA FAOT ET AL: "Efficacy of citric acid denture cleanser on the Candida albicans biofilm formed on poly(methyl methacrylate): effects on residual biofilm and recolonization process", BMC ORAL HEALTH, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 1, 23 June 2014 (2014-06-23), pages 77, XP021190394, ISSN: 1472-6831, DOI: 10.1186/1472-6831-14-77 *

Similar Documents

Publication Publication Date Title
ES2526640T3 (es) Composiciones para romper e inhibir la reconstitución de la biopelícula de heridas
BR112012018170B1 (pt) Agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos
CN108670889A (zh) 一种防治口腔溃疡的牙膏及其制备方法
CN1889965B (zh) 使用生物相容聚合物,制备一种化合物或制造一种医用设备
CN104619330B (zh) 用于治疗伤口和疮的包含次氯酸盐和氨基酸的制剂
Dixon et al. A review of equine paranasal sinusitis: medical and surgical treatments
Kästner et al. Removal of polyacrylamide gel (Aquamid®) from the lip as a solution for late-onset complications: our 8-year experience
WO2019213396A1 (fr) Formulations et méthodes d'administration pour la réduction et l'élimination d'inflammations induites par des agents pathogènes dans le corps humain
WO2016080158A1 (fr) Préparation d'un film biologique pour favoriser la cicatrisation et le revêtement des plaies, et la protection d'organes biologiques
CN102885849A (zh) 使用生物相容聚合物，制备一种化合物或制造一种医用设备
WO2019182975A1 (fr) Formulations comprenant des acides alpha hydroxy et procédés d'administration pour la réduction et l'élimination d'inflammations induites par des agents pathogènes dans le corps humain
Salmah et al. Synergistic effects of alcoholic extract of sweet basil (Ocimum basilicum L.) leaves and honey on cutaneous wound healing in rats
KR20000069990A (ko) 염증의 국소적 치료를 위한 제제를 제조하기 위한 디클로로벤질 알콜의 용도 및 디클로로벤질 알콜을 함유하는 제제
CN110381933A (zh) 用于控制生物膜的材料和方法
CN1562075A (zh) 生物活性玻璃治疗牙龈炎、牙出血以及解除牙松动症状的作用
Jennings et al. Surgical site infection after occlusion of the internal carotid artery with a thrombectomy catheter: Five cases
Harcourt‐Brown Dental disease in pet rabbits 3. Jaw abscesses
RU2582228C1 (ru) Способ профилактики и лечения послеоперационного воспаления полости рта
RU2296570C2 (ru) Способ лечения нагноившихся остаточных полостей печени после эхинококкэктомии
RU2545764C1 (ru) Способ лечения пародонтита
Horiuchi Anal and dental fistulae: Proposal for a novel treatment with ozone nanobubble saline washing
Qamar et al. Potential biochemical effects of honey in oral health care: a review.
KUSHTA et al. CORRECTION OF DYSBIOSIS AND ELIMINATION OF INFLAMMATION OF THE ORAL CAVITY IN PATIENTS WITH MALIGNANT TUMORS.
RU2789465C1 (ru) Способ профилактики и лечения патологических изменений зубочелюстной системы при пародонтозе
EP1455772B1 (fr) Milieu destine au traitement radical des tumeurs, des processus inflammatoires, des infections fongiques et d'autres affections des tissus, procedes diagnostique et prophylactique et procede de mise en oeuvre dudit milieu

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19724035

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08/03/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19724035

Country of ref document: EP

Kind code of ref document: A1